NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.783
+0.019 (2.43%)
At close: Sep 6, 2024, 4:00 PM
0.789
+0.006 (0.77%)
After-hours: Sep 6, 2024, 4:25 PM EDT
NKGen Biotech Employees
NKGen Biotech had 63 employees as of December 31, 2023.
Employees
63
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,270,063
Market Cap
20.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Athira Pharma | 67 |
| MEI Pharma | 46 |
| Inspira Technologies Oxy B.H.N. | 42 |
| Nephros | 31 |
| Brainstorm Cell Therapeutics | 29 |
| NeurAxis | 19 |
| Lipocine | 17 |
| SeaStar Medical Holding | 12 |
NKGN News
- 5 days ago - NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 16 days ago - NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report - GlobeNewsWire
- 5 weeks ago - NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
- 7 weeks ago - NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
- 7 weeks ago - NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors - GlobeNewsWire
- 3 months ago - NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 - GlobeNewsWire
- 3 months ago - NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 - GlobeNewsWire
- 3 months ago - NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire